Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_assertion type Assertion NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_head.
- NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_assertion description "[Third, rationally based combination therapies, including bortezomib with Akt, mammalian target of rapamycin, or histone deacetylase inhibitors, are active even in bortezomib-refractory MM.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_provenance.
- NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_assertion evidence source_evidence_literature NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_provenance.
- NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_assertion SIO_000772 22215754 NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_provenance.
- NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_assertion wasDerivedFrom befree-2016 NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_provenance.
- NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_assertion wasGeneratedBy ECO_0000203 NP950753.RA4MQRsSGdvZN2iOS_4X_wtpPo6ukbTQtLtsmThXVy_8g130_provenance.